These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7185532)

  • 1. Relative bioavailability of a standard and a sustained-release quinidine tablet.
    Gibson DL; Smith GH; Koup JR; Stewart DK
    Clin Pharm; 1982; 1(4):366-8. PubMed ID: 7185532
    [No Abstract]   [Full Text] [Related]  

  • 2. Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate.
    Taggart WV; Holyoak W
    Clin Ther; 1983; 5(4):357-64. PubMed ID: 6871920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state.
    Zinny MA; Taggart WV
    Clin Ther; 1984; 7(1):22-7. PubMed ID: 6518461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
    Yang XG; Nie SF; Bai HJ; Zhang GJ; Pan WS
    Yao Xue Xue Bao; 2005 May; 40(5):457-61. PubMed ID: 16220793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent.
    Regårdh CG; Johnsson G; Lundborg P; Perrson BA
    Arzneimittelforschung; 1977; 27(9):1716-8. PubMed ID: 21671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of a commercial sustained-release quinidine tablet compared to oral quinidine solution.
    Sawyer WT; Pulliam CC; Mattocks A; Foster J; Hadzija BW; Rosenthal HM
    Biopharm Drug Dispos; 1982; 3(4):301-10. PubMed ID: 7159686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enteric coated quinidine compared to sustained release preparations during repeated administration.
    Bakke OM; Aanderud L; Aslaksen A
    Acta Med Scand; 1980; 207(3):183-7. PubMed ID: 7368984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)].
    Knapp W; Lechleitner P
    Arzneimittelforschung; 1981; 31(9):1482-6. PubMed ID: 7197960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relative bioavailability of various quinidine preparations in man after a single oral dose].
    Terhaag B; Gieszinger U
    Pharmazie; 1982 Dec; 37(12):848-50. PubMed ID: 7163373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relative biological availability of quinidine VUFB retard tablets in dogs].
    Sedlmayer P; Sispera L
    Cesk Farm; 1983 Jul; 32(5):164-6. PubMed ID: 6883523
    [No Abstract]   [Full Text] [Related]  

  • 11. Single-dose comparative kinetics and bioavailability study of quinine hydrochloride, quinidine sulfate and quinidine bisulfate sustained-release in healthy male volunteers.
    Jamaludin A; Mohamed M; Navaratnam V; Mohamed N; Yeoh E; Wernsdorfer W
    Acta Leiden; 1988; 57(1):39-46. PubMed ID: 3245401
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of food on the comparative bioavailability of a fast- and slow-release dosage form of quinidine gluconate.
    Spénard J; Sirois G; Gagnon MA
    Int J Clin Pharmacol Ther Toxicol; 1983 Jan; 21(1):1-9. PubMed ID: 6832862
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration.
    Greenblatt DJ; Pfeifer HJ; Ochs HR; Franke K; MacLaughlin DS; Smith TW; Koch-Weser J
    J Pharmacol Exp Ther; 1977 Aug; 202(2):365-78. PubMed ID: 577934
    [No Abstract]   [Full Text] [Related]  

  • 14. [Bioavailability of two quinidin drug-released products (author's transl)].
    Sado PA; Le Verge R; Devissaguet JP
    Therapie; 1979; 34(6):713-26. PubMed ID: 547445
    [No Abstract]   [Full Text] [Related]  

  • 15. Absolute bioavailability of quinidine in two sustained release preparations.
    Amlie JP; Storstein L; Olsson B; Fremstad D; Jacobsen S
    Eur J Clin Pharmacol; 1979 Aug; 16(1):45-8. PubMed ID: 499299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serious bioavailability problems with a generic prolonged-release quinidine gluconate product.
    Meyer MC; Straughn AB; Lieberman P; Jacob J
    J Clin Pharmacol; 1982; 22(2-3):131-4. PubMed ID: 7068936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics and relative bioavailability of KC-404 sustained release tablets in healthy volunteers].
    Li T; Pang Y; Wang Z; Jia Y; Cheng Q; Sun J
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):541-3. PubMed ID: 12910715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of two brands of quinidine gluconate administered on a multiple-dose regimen.
    Smith TC; Kinkel AW
    Curr Ther Res Clin Exp; 1977 Jan; 21(1):128-34. PubMed ID: 401707
    [No Abstract]   [Full Text] [Related]  

  • 19. Bioavailability of three commercial sustained-release tablets of quinidine in maintenance therapy.
    Huynh-Ngoc T; Chabot M; Sirois G
    J Pharm Sci; 1978 Oct; 67(10):1456-9. PubMed ID: 702302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative bioavailability and release pattern of whole and halved sustained-release theophylline tablets.
    Leeds NH; Gal P; Purohit AA; Walter JB
    Clin Pharm; 1982; 1(2):163-4. PubMed ID: 7185516
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.